Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/14—Ectoparasiticides, e.g. scabicides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

• the present invention relates to the prevention or treatment of parasitic arthropod infestations of animals.
• Demodex spp. mites are normal commensals of the skin of a number of animals parasitising within the sebaceous glands connected to the hair follicles. Should their numbers increase dramatically, they are capable of producing a disease known as demodicosis or demodectic mange.
• Demodicosis is a non contagious inflammatory parasitic dermatosis caused by overpopulation of the follicular Demodex mites. Demodicosis can be classified as localized or generalized according to the extent of the lesions. Localized demodicosis is a benign disease and most cases resolve spontaneously within six to eight weeks.
• Generalized demodicosis is a severe disease with generalized lesions that are usually aggravated by secondary bacterial infections (pyodemodicosis). Accompanying pododermatitis is common. Dogs can have systemic illness with generalized lymphadenopathy, lethargy, and fever when deep pyoderma, furunculosis, or cellulitis is seen. Diagnosis is not difficult, as deep skin scrapings or hair plucking reveal mites, eggs, and larval forms in high numbers.
• Therapeutic options that are currently available include amitraz, ivermectin, milbemycin oxime, moxidectin orally and moxidectin topically, mostly to be given at multiple occasions (daily, weekly or monthly) for periods of three months or more.
• a problem frequently encountered with the treatment of demodicosis in dogs is the inability to ensure that a dog is absolutely free from mites after treatment and re-infestation can be detected months after completion of a treatment that was initially considered to be successful.
• the current invention provides to use an isoxazoline compound of formula (I)
• R 1 halogen, CF 3 , OCF 3 , CN,
• n integer from 0 to 3, preferably 1, 2 or 3,
• R 2 C 1 -C 3 -haloalkyl, preferably CF 3 or CF 2 Cl,
• T 5- or 6-membered ring, which is optionally substituted by one or more radicals Y,
• Y methyl, halomethyl, halogen, CN, NO 2 , NH 2 —C ⁇ S, or two adjacent radicals Y form together a chain, especially a three or four membered chain;
• Q X—NR 3 R 4 or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals;
• X CH 2 , CH(CH 3 ), CH(CN), CO, CS,
• R 3 hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,
• Z A hydrogen, halogen, cyano, halomethyl (CF 3 );
• R 4 hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;
• R 3 and R 4 together form a substituent selected from the group consisting of:
• This invention also is directed to the isoxazoline compound as described in this application or a pharmaceutical composition comprising such isoxazoline compound for use in the treatment of generalized demodicosis in animals comprising an effective amount of an isoxazoline compound as described in this specification, and, in case of the pharmaceutical formulation, a pharmaceutically acceptable carrier.
• the current invention further provides a method of controlling Demodex spp. mites in dogs comprising a single administration of an isoxazoline compound as described in this specification.
• demodicosis of mammals can be treated by administering an effective amount of an isoxazoline compound as described in this application. It has been found that a single administration of such an isoxazoline compound resulted in a complete miticidal effect against Demodex spp. mites and a high efficacy against generalized demodicosis in dogs.
• the prior art administration of the compounds additionally bear a high risk of side effects of such treatments because relatively high dosages of the miticidal compounds over an extended time period resulted in some cases in severe toxic side effects in treated animals, especially for ivermectin sensitive breeds of dogs such as e.g. collies.
• the isoxazoline compound for use in the current invention can be described by Formula (I):
• R 1 halogen, CF 3 , OCF 3 , CN,
• n integer from 0 to 3, preferably 1, 2 or 3,
• R 2 C 1 -C 3 -haloalkyl, preferably CF 3 or CF 2 Cl,
• T 5- or 6-membered ring, which is optionally substituted by one or more radicals Y,
• Y methyl, halomethyl, halogen, CN, NO 2 , NH 2 —C ⁇ S, or two adjacent radicals Y form together a chain CH—CH ⁇ CH—CH, N—CH ⁇ CH—CH, CH—N ⁇ CH—CH, CH—CH ⁇ N—CH, or CH—CH ⁇ CH—N, HC ⁇ HC—CH, CH—CH ⁇ CH, CH ⁇ CH—N, N—CH ⁇ CH;
• Q X—NR 3 R 4 or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals Z A , Z B Z D ;
• X CH 2 , CH(CH 3 ), CH(CN), CO, CS,
• R 3 hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,
• R 4 hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl; or
• R 3 and R 4 together form a substituent selected from the group consisting of:
• Z A hydrogen, halogen, cyano, halomethyl (CF 3 ).
• T is selected from
• T-1, T-3 and T-4 the radical Y is hydrogen, halogen, methyl, halomethyl, ethyl, haloethyl.
• R 3 , R 4 , X and Z A are as defined above.
• Preferred isoxazoline compounds of Formula (I) for use in the current invention are:
• a more preferred isoxazoline compound for use in the current invention has the Formula (II),
• R 1a , R 1b , R 1c are independently from each other hydrogen, Cl or CF 3 , preferably R 1a and R 1c are Cl or CF 3 and R 1b is hydrogen,
• Y is methyl, bromine, Cl, F, CN or C(S)NH 2 , and
• R 3 is H and R 4 is —CH 2 —C(O)—NH—CH 2 —CF 3 , —CH 2 —C(O)—NH—CH 2 —CH 3 , —CH 2 —CH 2 —CF 3 or —CH 2 —CF 3
• the isoxazoline compound is 4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide (CAS RN 864731-61-3—USAN fluralaner).
• the isoxazoline compound is (Z)-4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxyimino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
• the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide (CAS RN 1164267-94-0) that was disclosed in WO2009/0080250.
• the isoxazoline compound is Ethanone, 1-[5′-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]spiro[azetidine-3,1′(3′H)-isobenzofuran]-1-yl]-2-(methylsulfonyl)—(Sarolaner) (CAS RN— 1398609-39-6).
• the isoxazoline compound is 2-Thiophenecarboxamide, 5-((5S)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl)-3-methyl-N-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)—(INN Lotilaner) (CAS RN— 1369852-71-0).
• the isoxazoline compound is 4-[5-[3-Chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (CAS RN 1093861-60-9, USAN—afoxolaner) that was disclosed in WO2007/079162—.
• the isoxazoline compound is 5-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide (CAS RN 1231754-09-8) that was disclosed in WO2010/070068.
• Isoxazoline compounds and their use as antiparasitics are e.g. described in US patent application US 2007/0066617, and International Patent applications WO 2005/085216, WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO 2010/070068 and WO 2010/079077.
• the method (or use) of this invention comprises to use racemic mixtures, for example, equal amounts of the enantiomers of such isoxazoline compounds as described above.
• the method of this invention includes isoxazoline compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of such isoxazoline compounds.
• compositions for use in the current invention have at least a 50% enantiomeric excess; more preferably at least a 75% enantiomeric excess; still more preferably at least a 90% enantiomeric excess; and the most preferably at least a 94% enantiomeric excess of the more active isomer.
• enantiomerically pure embodiments of the more active isomer are enantiomerically pure embodiments of the more active isomer.
• Isoxazoline compounds as described above can comprise additional chiral centers.
• the method of this invention comprises racemic mixtures as well as enriched and essentially pure stereo configurations at these additional chiral centers.
• isoxazoline compound in this specification includes enantiomers, salts and solvates as well as N-oxides thereof that can be produced by conventional methods.
• treating or “treat” or “treatment” is intended the application or administration of a compound or composition to an animal that has a parasitic infestation for the eradication of the parasite or the reduction of the number of parasites, infesting the animal (eliminate existing parasites).
• the effect can be e.g. ovicidal, larvicidal nymphicidal, or adulticidal or a combination thereof.
• the effect can manifest itself directly, i.e. killing the parasites either immediately or after some time has elapsed, for example when molting occurs, or by destroying their eggs, or indirectly, e.g. reducing the number of eggs laid and/or the hatching rate.
• an “effective amount,” is the amount or quantity of an isoxazoline compound as described above that is required to treat Demodex spp. infestations of animals, i.e. to alleviate or reduce parasite numbers on an animal, and/or to inhibit the development of parasite infections on an animal, in whole or in part.
• the parasite count is reduced, after a first administration, by 5% to about 100%, preferably more than 50%, more than 70%, more than 90%, more than 95%, more than 99%, especially 100%.
• the effective amount results in microscopical cure, i.e. that no Demodex spp. mites are present in the deep skin scrapings of affected skin (preferably three to five scrapings of most severely affected areas), preferably taken at several time points.
• the effective amount for treatment of generalized demodicosis additionally leads to diminishing or resolution of clinical signs of demodicosis as described in this application.
• effective (dosage) amount of isoxazoline compounds are between 1 mg/kg bodyweight of the treated animal and 50 mg/kg bodyweight, or 5 mg/kg bodyweight to 45 mg/kg bw, or 10 mg/kg bw to 40 mg/kg bw, or 20 to 30 mg/kg bw. In one embodiment the effective dosage is 25 mg/kg bodyweight.
• a single dose of an effective amount of the isoxazoline compound is administered to a mammal, especially dog, that is infested with Demodex spp. mites.
• a single dose of an effective amount of the isoxazoline compound is administered to a dog that has been diagnosed with a generalized canine demodicosis.
• two doses of an effective amount of the isoxazoline compound are administered to a mammal, especially dog, that is infested with Demodex spp. mites.
• a two doses of an effective amount of the isoxazoline compound are administered to a dog that has been diagnosed with a generalized canine demodicosis.
• three doses of an effective amount of the isoxazoline compound are administered to a mammal, especially dog, that is infested with Demodex spp. mites.
• a three doses of an effective amount of the isoxazoline compound are administered to a dog that has been diagnosed with a generalized canine demodicosis.
• Systemic administration is an administration at a site remote from a site wherein at least a portion of the target parasites reside. With systemic administration, at least a portion of the isoxazoline compound reaches the target parasite via the animal recipient's bloodstream, other body fluids (lymph fluids), and/or tissues (e.g., skin or fat tissue). This is in contrast to “contact activity” were the surface of the parasite body is directly exposed to the isoxazoline compound. Typically, the parasite ingests the systemic administered isoxazoline along with the animal recipient's blood, other body fluids, and/or tissue. Systemic administration may be achieved in several forms, e.g. oral, parenteral or via topical administration wherein the isoxazoline compound is transdermally absorbed.
• the isoxazoline compound is systemically administered via an oral route in a unit dosage form, such as, for example, a soft or hard capsule, a pill, a powder, granules, a tablet (e.g., a chewable tablet), a paste, a solution, a suspension (aqueous or non-aqueous), an emulsion (oil-in-water or water-in-oil), an elixir, a syrup, a bolus, a drench, or via the animal recipient's feed or drinking water.
• oral administration can be performed via the animal recipient's feed or drinking water e.g. it may be intimately dispersed in the animal recipient's regular feed, used as a top dressing, or in the form of pellets or liquid that is added to the finished feed.
• One form of oral administration is a dosage form, e.g. a chewable composition, such as a chewable tablet.
• a chewable composition such as a chewable tablet.
• examples of chewable tablets comprising isoxazoline compounds of formula (I) were described in WO2013/150052 and WO2013/150055.
• the composition of the chewable tablets that is disclosed in the examples of these documents is incorporated by reference.
• Alternative chewable tablets are described in WO2013/119442.
• Oral veterinary compositions in the form of a “chewable tablet”, sometimes referred to as “soft chewable compositions” or “soft chew”, are usually convenient to administer to certain animals, particularly cats and dogs, preferably dogs, and may be used effectively to dose veterinary medicine to these animals.
• a “Chewable tablet”, “Soft chew” or “Soft chewable pharmaceutical product” is intended to mean a pharmaceutical unit dose that is solid at room temperature and that is after oral administration soft to chew by the animal and which is functionally chewy because the product has some plastic texture during the process of mastication in the mouth. Such soft chews have a softness that is similar to a cooked ground meat petty.
• the chewable tablet or soft chew comprises a carrier and other non-active ingredients.
• the isoxazoline compound alternatively (or additionally) may be systemically administered topically using a transdermal formulation (i.e., a formulation that passes through the skin). Alternatively (or additionally), the composition may be systemically administered topically via the mucosa.
• the isoxazoline composition alternatively (or additionally) may be systemically administered parenterally, such as via intramuscular injection, intravenous injection, subcutaneous injection, implant (e.g., subcutaneous implant), infusion, bolus, etc.
• the animals may receive an isoxazoline compound as defined earlier once, two times or three times until the Demodex mite infestation is controlled and the generalized demodicosis is successfully treated.
• One treatment provides effectiveness against Demodex spp. mites for at least 4 weeks, 8 weeks, 12 weeks, 16 weeks or 20 weeks, or 24 weeks.
• the isoxazoline compound can be administered to all species of animals that have Demodex spp. infestation or require treatment of a demodicosis.
• the recipient of the product may be a livestock animal, e.g. sheep, cattle, pig, goat; or a companion animal, e.g. dog, cat, or horse.
• a livestock animal e.g. sheep, cattle, pig, goat
• a companion animal e.g. dog, cat, or horse.
• companion animals e.g. dogs or cats, especially dogs.
• Demodex spp. mites that can be controlled by the use according to the current invention are e.g. Demodex canis, Demodex injai, Demodex cornei, Demodex. cati, Demodex gatoi, Demodex bovis, Demodex ovis, Demodex caprae, Demodex aries.
• a “ Demodex mite infestation” refers to the presence of parasites in numbers that pose a risk of r harm to animals.
• Demodicosis is diagnosed by clinical evaluation and deep skin scrapings that is analysed using a microscope for mites present. Demodicosis is considered generalized when five or more areas of localized disease are observed, or pododemodicosis is observed on two or more feet, or when an entire body region is involved. Demodicosis can also be categorized as either juvenile (dogs up to 18 months of age), adult onset (dogs generally older than four years of age with no previous history of disease), or chronic generalized (persisting disease for at least six months).
• the administration allows to completely inhibit or kill the Demodex spp. mites present on the animal that cause the demodicosis.
• microscopic cure i.e. multiple skin scrapings without any Demodex mites (eggs, larvae, nymphs and adults) is obtained by the administration of the isoxazoline compound.
• the administration of the isoxazoline compound e.g. fluralaner is able to reduce the clinical signs of the demodicosis, and preferably at least one of the dermatological signs, e.g. the skin lesions, such as erythema, casts, pustules, scales and crusts, exudation, ulceration and hair loss up to alopecia is reduced significantly compared to the situation before treatment or without treatment.
• the dermatological signs e.g. the skin lesions, such as erythema, casts, pustules, scales and crusts
• the administration of the isoxazoline compound e.g. fluralaner is able to cure together with a symptomatic therapy (e.g. antibiotics or antiseptics) the appearance of systemic symptoms such as generalized lymphadenopathy, lethargy, and fever.
• a symptomatic therapy e.g. antibiotics or antiseptics
• the isoxazoline compound as described in this application can be used concurrently with suitable antibiotics in order to control the secondary bacterial skin infection pyoderma that is usually associated with generalized demodicosis.
• Superficial pyoderma can be treated with oral antibiotics or topical antibiotics.
• topical treatment with benzoyl peroxide or chlorhexidine-based shampoos will be useful to control the bacterial secondary infections.
• the study was designed as a parallel group, blinded, randomized, single centre, and positive controlled efficacy study.
• Bravecto® administered as chewable tablets on a single occasion was the test product and Advocate®, administered three times at 28 day intervals (according to the product label) was included as a positive control.
• the test system was the individual dog. Dogs with clinical signs of generalized demodicosis, e.g. erythema, hair loss, comedones, follicular casts and crusts were enrolled, with consent from their owners, in the study and were returned to their owners on completion of the animal phase.
• generalized demodicosis e.g. erythema, hair loss, comedones, follicular casts and crusts
• Dogs included in the study were mostly mongrels and of both sexes, older than 12 months, weighed between 3.5 and 13.7 kg, and except for clinical signs of generalized demodicosis, the dogs were healthy and as far as could be determined the dogs had not been treated with a glucocorticoid or any product with a miticidal effect for at least 12 weeks prior to inclusion. Additional requirements for inclusion were that deep skin scrapings performed before treatment had to be positive for Demodex spp. mites.
• Each dog was acclimatized to the housing and maintenance conditions for at least 14 days before treatment.
• all dogs were treated subcutaneously with an antibiotic (cefovecin), appropriate for the treatment of pyoderma on Days ⁇ 14, ⁇ 1, 13 and 27.
• cefovecin antibiotic
• deep skin biopsies were taken from each dog after sedation. The biopsies indicated that exudative pyoderma was present in two dogs in each group on Day ⁇ 14 and that it had cleared by Day 27.
• Chronic dermatitis, epidermal acanthosis and hyperkeratosis was present and unchanged in all dogs on both occasions. No inflammatory cells or bacteria were observed in the Day 27 biopsies and antimicrobial therapy was discontinued. Twice during acclimatization (Day ⁇ 14 and Day ⁇ 1) and on Days 27/28, 56 and 84 after treatment each dog was clinically examined by a veterinarian.
• the dogs were weighed on a calibrated and verified electronic scale on Days ⁇ 2, 13, 27, 41, 55, 69 and 84 for dose calculation for treatment, for the use of sedatives for skin scrapings and to document the body weight during the study period. General health observations were performed daily throughout the complete study period.
• Deep skin scrapings ( ⁇ 4 cm 2 ) were made from five sites on each dog on Days ⁇ 4, 28, 56 and 84 and were examined under a stereomicroscope for the presence of Demodex spp. mites. Skin scrapings of the dogs treated with Advocate® were performed on Day 28 and Day 56, before the second or third treatment was applied, respectively. The same sites and/or sites of new lesions were scraped at each subsequent examination.
• the primary assessment variable in the study was the decrease in number of mites counted in skin scrapings (immature and adult live mites combined) following treatment.
• Mpre was the mean number of pre-treatment mite counts
• Mpost the mean number of post-treatment mite counts
• Treatment with Bravecto® chewable tablets resulted in a reduction in the mean mite number present in skin scrapings of 99.8% on Day 28, and of 100% on Days 56 and 84 after treatment.
• the treatment with Advocate® resulted in a reduction in the mean mite number present in skin scrapings of 98.0% on Day 28, of 96.4% on Day 56, and of 94.7% on Day 84.
• Hair re-growth compared to the proportion of the body area covered by hair prior to treatment is summarized in Table 3.
• Days 56 and 84 after initiation of treatment hair re-growth on the majority of dogs in both groups exceeded the hair-coat of the dogs by 90% compared with the pre-treatment assessment.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Dermatology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Zoology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=52146273

Family Applications (3)

Family Applications After (2)

Country Status (14)

Cited By (2)

Families Citing this family (6)

Family Cites Families (19)

• 2015
  • 2015-12-21 DK DK15817303.9T patent/DK3236960T3/da active
  • 2015-12-21 PL PL15817303.9T patent/PL3236960T3/pl unknown
  • 2015-12-21 BR BR112017013286-9A patent/BR112017013286A2/pt not_active Application Discontinuation
  • 2015-12-21 EP EP21213190.8A patent/EP4008329B1/en active Active
  • 2015-12-21 ES ES15817303T patent/ES3018234T3/es active Active
  • 2015-12-21 CN CN202210404756.7A patent/CN114681453A/zh active Pending
  • 2015-12-21 FI FIEP21213190.8T patent/FI4008329T3/fi active
  • 2015-12-21 AU AU2015371175A patent/AU2015371175B2/en active Active
  • 2015-12-21 PT PT158173039T patent/PT3236960T/pt unknown
  • 2015-12-21 EP EP25179725.4A patent/EP4599830A3/en active Pending
  • 2015-12-21 DK DK21213190.8T patent/DK4008329T3/da active
  • 2015-12-21 JP JP2017533378A patent/JP6706262B2/ja active Active
  • 2015-12-21 FI FIEP15817303.9T patent/FI3236960T3/fi active
  • 2015-12-21 RU RU2017126029A patent/RU2709198C2/ru active
  • 2015-12-21 CN CN201580069964.4A patent/CN106999475B/zh active Active
  • 2015-12-21 PT PT212131908T patent/PT4008329T/pt unknown
  • 2015-12-21 US US15/537,547 patent/US20170348286A1/en not_active Abandoned
  • 2015-12-21 EP EP15817303.9A patent/EP3236960B1/en active Active
  • 2015-12-21 PL PL21213190.8T patent/PL4008329T3/pl unknown
  • 2015-12-21 WO PCT/EP2015/080744 patent/WO2016102437A1/en not_active Ceased
  • 2015-12-21 ES ES21213190T patent/ES3037078T3/es active Active
  • 2015-12-21 CA CA2971296A patent/CA2971296A1/en active Pending
• 2018
  • 2018-04-04 US US15/944,967 patent/US10799483B2/en active Active
• 2020
  • 2020-09-09 US US17/015,263 patent/US20200405692A1/en not_active Abandoned
• 2021
  • 2021-06-04 AU AU2021203686A patent/AU2021203686A1/en not_active Abandoned
• 2023
  • 2023-08-25 AU AU2023219972A patent/AU2023219972B2/en active Active

Also Published As

Similar Documents

Legal Events